Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

tudy of Voreloxin and Cytarabine Indicates Activity of Combination Regimen

Preliminary results were also presented today from Sunesis' ongoing dose-escalating Phase 1b clinical trial evaluating voreloxin in combination with cytarabine, the current standard of care in patients with relapsed and/or refractory AML. The Phase 1b trial is designed to evaluate the safety and tolerability, and to provide a preliminary assessment of anti-leukemic activity, of escalating doses of voreloxin when administered on days one and four with a fixed dose of 400 mg/m2/day of cytarabine given as a continuous infusion for five days. Of twelve evaluable patients in the first three cohorts, three patients have achieved CRs (one at 20 mg/m2 of voreloxin and two at 34 mg/m2 of voreloxin). Six patients were enrolled in cohort 4 (50 mg/m2 of voreloxin), and no dose limiting toxicities have been observed thus far at this dose. Patients are now being enrolled in cohort 5 at 70 mg/m2 of voreloxin. Voreloxin pharmacokinetics have so far been unaffected by the combination with cytarabine.

"We are very pleased by the interim results reported today from our Phase 1b combination study of voreloxin with cytarabine. We look forward to reporting results from this study later in the year, including CR rates at 50 mg/m2 and higher dose levels of voreloxin," continued Dr. Michelson.

These data were presented today in a poster titled "Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients >/= 60 Years Old Compared to <60 Years Old: Results of a Phase 1b Study" (Abstract #0515) at the 13th Congress of the European Hematology Association. A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally re
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "North America Mammography Market ... 2019)"  report to their offering. ... is a detailed type of imaging that ... breasts. A mammography exam, called a mammogram, ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: ... Forecast and Market Analysis to 2022 - Event-Driven Update ... dominated by generics and GlaxoSmithKline,s Benlysta is the only ... more than 50 years. Following Benlysta,s launch, patients, uptake ... price-tag Benlysta has managed to grow the lupus market ...
Breaking Medicine Technology:North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... third quarter 2011 financial results after the market closes on ... webcast will be held on Thursday, November 3, 2011, at ... To participate in the call, please dial 877-303-1298 (for U.S. ...
... 2011 IDenta Corp. (OTC: IDTA) CEO Yaacov Shoham today ... are succeeding in making sales in many new markets, including ... We have received an order for 2000 detectors from the ... In the past several months we have ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2
(Date:5/27/2015)... Cincinnati Veterans Affairs Medical Center invites caregivers ... from noon-2p.m. in the auditorium. This event provides ... full-time assistance to Veterans in their homes. ... conducted by the medical center staff. In order ... home, the caregiver must provide monthly care including room ...
(Date:5/27/2015)... Thermage was the first to come out with a ... coinciding with the release of NXT or CPT, the second-generation ... was the first practice in New York to debut the ... that had never been achieved before non-surgically. Even today, ... by many as the leading skin tightening device. The ...
(Date:5/27/2015)... May 27, 2015 StatRad, a leading ... is pleased to introduce Mr. Chris E. Hafey as ... a proven track record of leading new development projects ... domain. He most recently served as the Chief Technology ... role of Chief Architect for Vital Images. , "I ...
(Date:5/27/2015)... Western University of Health Sciences’ 34th Annual Commencement ... and one profound last. , The May 20-22, 2015 ... time the university surpassed more than 1,000 graduates at ... Biomedical Sciences (GCBS) alumnus graduated from the College of ... fifth and final ceremony of its three-day Commencement – ...
(Date:5/27/2015)... Ticket Down is a reputable source for 2015 ... super hot during the 2014-15 NBA season and they delighted their ... final score of 118-88. , For the Cavaliers, this ... when they lost to the San Antonio Spurs. Once Lebron ... Cavaliers making it to the NBA finals increased tenfold. The ...
Breaking Medicine News(10 mins):Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2Health News:StatRad Introduces Mr. Chris E. Hafey as Chief Technology Officer, and the Release of its Advanced Pure HTML5 DICOM Image Uploader 2Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 2Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 3Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 4Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 5Health News:Cavs NBA Finals Tickets: Ticket Down Slashes Ticket Prices on Cleveland Cavaliers 2015 NBA Finals Tickets at Quicken Loans Arena and Offers Valuable Promo Code 2
... Scientists have unraveled in unprecedented detail the cascade of events ... virus whose assault on the nervous system continues unabated despite ... years in the rest of the body. , The new ... a protein that is central to HIV,s attack on cells ...
... should shop wisely, experts say , , FRIDAY, Nov. 14 ... Part D prescription drug coverage program for 2009 kicking ... a plan carefully because premiums and covered medications can ... the fourth year of the Medicare Part D prescription ...
... from gastroesophageal reflux disease (GERD) can now be helped with the ... only physician in San Francicso to offer this non-invasive alternative to ... ... 2008 -- EsophyX™ is the first device for incisionless reconstructive surgical ...
... of the most debilitating diseases known to man, and new findings ... News Report website. To read the entire report about the ... , ... Boca Raton, Fla. (PRWEB) November 14, 2008 ...
... which young people livefamilies, peers, schools, and neighborhoodscontribute both ... risk from one area possibly being magnified or decreased ... a new longitudinal study conducted by researchers at the ... of California at Davis, and the University of California ...
... may sometimes work best, researchers say , , THURSDAY, Nov. ... therapy for irritable bowel syndrome (IBS) may be older, ... a new study finds. , According to researchers, these ... the availability of newer (and more expensive) drugs, some ...
Cached Medicine News:Health News:Researchers identify toehold for HIV's assault on brain 2Health News:Researchers identify toehold for HIV's assault on brain 3Health News:Researchers identify toehold for HIV's assault on brain 4Health News:Enrollment for Medicare Drug Plans Begins Again 2Health News:Enrollment for Medicare Drug Plans Begins Again 3Health News:Revolutionary Procedure for the Treatment of Gastroesophageal Reflux Now Possible in San Francisco Thanks to Dr. Paul Cirangle 2Health News:Revolutionary Procedure for the Treatment of Gastroesophageal Reflux Now Possible in San Francisco Thanks to Dr. Paul Cirangle 3Health News:Alzheimer's Disease Cutting Edge Research Announced on Natural Health News Report Website 2Health News:Families, friends, schools and neighborhoods contribute to adolescent alcohol misuse 2Health News:Peppermint Oil, Fiber Can Fight Irritable Bowel 2Health News:Peppermint Oil, Fiber Can Fight Irritable Bowel 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: